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Abstract 
The idiopathic inflammatory myopathies are a heterogeneous group of autoimmune muscle 
disorders with distinct clinical and pathological features and underlying immunopathogenic 
mechanisms. Traditionally, CD4
+
Th1cells or CD8
+
 cytotoxic effector T cells and typeI/II 
interferons have been primarily implicated in the pathogenesis of the inflammatory 
myopathies. The presence of IL-17A producing cells in the inflamed muscle tissue of myositis 
patients and the results of in vitro studies suggest that IL-17A and the Th17 pathway may 
also have a key role in these diseases.  The contribution of IL-17A to other chronic 
inflammatory and autoimmune diseases has been well established and clinical trials of IL-
17A inhibitors are now at an advanced stage. However the precise role of IL-17A in the 
various forms of myositis and the potential for therapeutic targeting is currently unknown 
and warrants further investigation.  
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1. Introduction  
The idiopathic inflammatory myopathies (IIIMs) are a heterogeneous group of autoimmune 
muscle disorders that include dermatomyositis (DM),polymyositis (PM), inclusion body 
myositis (IBM), and the immune-mediated necrotising myopathies (IMNM)[1].The 
association with myositis-specific autoantibodies and certain HLA alleles,and the 
overexpression of Class I and II major histocompatibility complex molecules by muscle cells 
and predominance of Tcells and Bcellsinaffected muscles has implicated an autoimmune 
origindespite the fact that the target autoantigensin DM, PM and IBM have yet to be 
identified. Whilst these conditionsshare a number of common properties, namely muscle 
weakness and inflammation, they have distinct clinical and pathological features and are 
thought to have different underlying immunopathogenic mechanisms.  These have been 
reviewed previously [2-4], as have the underlying cellular and molecular mechanisms that 
may contribute to the muscle weakness in the IIMs[5]Dermatomyositis is usually regarded 
asa CD4+ T-cell-driven diseasein which a complement-dependent humorally mediated attack 
on the vascular endothelium results in skin and muscle injury[6, 7]).In contrast, both PM and 
IBMare thought to share aCD8
+
T-cell-mediated autoimmune process[8, 9]where muscle 
fibres expressing MHC-I antigens are invaded by CD8+T lymphocytes which are clonally 
expandedin situ, and drive the induction of cytotoxic necrosis through the liberation of 
perforins and granzymes[10].In spite of this, it is recognised that the involvement of these T 
cell subsets is not necessarily exclusive and that there is a certain amount of overlap in the 
immunopathological phenotype in the different forms of IIM.Moreover, the demonstration 
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of a subset of CD28null CD4+ and CD8+ cells with a natural killer cell phenotype in DM and PM 
tissues[11]suggests that there may be multiple mechanisms of T cell mediated cytotoxicity. 
In contrast to the other IIMs, IBM is distinguished by the fact that the inflammatory process 
is accompanied by myodegenerative changes and abnormal protein aggregation and 
inclusion body formation in muscle fibres [12].  
The majority of research to date has implicated CD4
+
 T-helper (Th1) cells or CD8
+
 cytotoxic 
effector T cells in the pathogenesis of the inflammatory myopathies, as evidenced by the 
detection of a type 1 interferon profile in both DM and PMand a Th1 immune profile in 
IMNM[13, 14]. Interleukin-17 (IL-17) and the Th17 subset of CD4
+
 cells have been strongly 
implicated in the pathogenesis of a number of other autoimmune diseases including 
psoriasis, rheumatoid arthritis and multiple sclerosisleading to the development ofIL-17 
targeted monoclonal antibody therapies. In this review we summarise recent observations 
on IL-17 and the Th17 pathway in the inflammatory myopathies andtheir potential as novel 
therapeutic targetsfor the treatment of these diseases.  
2. Immunopathogenic mechanisms  
2.1 Polymyositis and inclusion-body myositis 
In PM and IBM CD8
+
 T cells are considered to be the primary effector cells mediating 
muscle-fibre injury[8, 9, 15]These cytotoxic T cells target muscle fibres expressingMHC Class 
I molecules and co-stimulatory molecules[16-19]The muscle fibres may therefore  act as 
antigen presenting cells [20, 21]and have been postulated to form immunological synapses 
with the T - cell receptors (TCRs) of the auto-invasive, clonally expanded CD8
+
T cells[2]. 
These T cells have been shown to be activated, expressing ligands specific for the co-
stimulatory molecules expressed by the muscle fibres[2]. Matrix-metalloproteinases 
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(MMPs) are thought to facilitate the transendothelial migration of T cells and their 
attachment to the surface of the muscle fibres[2]. The T cells also display cytotoxic 
properties by releasing perforin granules which are directed to the muscle fibres resulting in 
necrosis[10]. Cytokines such as IFN-ƴ, IL-1 and TNF secreted by activated CD8+ T cells may 
also contribute to muscle damage through a direct myocytotoxic effect[1].  
 
2.2 Dermatomyositis 
The disease process in DM is thought to be initiatedby antibodies directed against as yet 
unknown antigens expressed by the vascular endothelium activating the complement 
pathway[1]. However, endothelial cell specific autoantibodies have as yet not been 
identified.  Membrane attack complexes (MAC) form on the endomysial capillaries[6, 7]and 
are thought to cause endothelial cell necrosisleading to capillary depletionand muscle 
ischaemia[22-24] although the mechanisms leading to capillary loss have yet to be fully 
elucidated.  It is postulated that deposition of immunoglobulins on intramuscular capillaries 
activates the complement cascade, triggering the production of pro-inflammatory cytokines 
and chemokines, which in turn up-regulate the expression of adhesion molecules on 
endothelial cells leading to further recruitment of B cells, T cells and macrophages and 
interferon-α producing plasmacytoid dendritic cells [1, 25]. The release of other cytokines 
and soluble mediators such as TNF and NO by the activated T and B cells may further 
enhance the inflammatory processes taking place in the muscle[4]. Multiple findings 
indicate that upregulation of the Type 1 interferon pathway plays a prominent role in the 
disease pathogenesis in DM[26, 27]although it is not specific to DM[29]. 
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2.3 Myositis Specific Autoantibodies 
Myositis-specific autoantibodies (MSA) that target various ubiquitous autoantigens are well 
documented in both DM and PM, and more recently also in IMNM and IBM, and their 
potential value as diagnostic biomarkers is being increasingly recognised[30-34].  The best 
characterised are the antisynthetase antibodies which target a group of cytoplasmic 
aminoacyl tRNA synthetases[35]the most prevalent of which isanti-Jo-1 (anti-histidyl tRNA 
synthetase) which is present in about 20% of cases of PM and DM and is associated with the 
antisynthetase syndrome[36, 37]Other less common antisynthetases include anti-PL-12 
(alanyl-tRNA synthetase), anti-PL-7 (threonyl-tRNA synthetase), anti-EJ (glycyl-tRNA 
synthetase), anti-OJ (isoleucyl-tRNA synthetase), anti-KS (asparaginyl-tRNA synthetase), 
anti-Zo (phenylalanyl-tRNA synthetase) and anti-Ha (tyrosyl-tRNA synthetase) [38].In DM 
antibodies to Mi-2, which is a component of the nucleosome remodelling deacetylase 
complex, has a high specificity, particularly for the adult form of the disease[39, 40].More 
recently, a number of newer autoantibodies associated with particular subgroups of DM 
cases have been characterised including anti-TIF-1α/γ, anti-MDA5 and anti-NXP-2 and these 
have been reviewed elsewhere[31]. 
 
There is increasing evidence that in addition to their role as biomarkers MSA may also play a 
part in inducing and sustaining the autoimmune process in the IIM.  For example, a number 
of studies have shown that there is a correlation between serum levels of anti-Jo-1 
antibodies and both disease activity [42] and muscle damage [41], suggesting that the 
antibody has a causative role.  In addition, histidyl-tRNA synthetase and Mi-2 are over-
expressed in muscle tissue in PM and DM[43] and expression of Mi-2 has been shown to 
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beincreased in regenerating fibres in DM muscles and in human myoblasts in culture[31, 
44].  These observations have led to the suggestion that enhanced tissue expression of 
these autoantigens as part of the repair process in muscle may play a critical role in 
maintaining an autoantibody response and the ongoing autoimmune process in PM and 
DM[31, 45].  MSA such as histidyl-tRNA synthetase may also play a part in the recruitment 
of T cells and dendritic cells by activating chemokine receptors on these cells [46]. 
 
2.4Cytokine and Chemokine Involvement 
A common pathogenic mechanism inthe inflammatory myopathies is the specific migration 
of T cell subsets to the muscle tissue which involves activation of leukocytes, adhesion to 
the vasculature and transendothelial migration. Molecules associated with T cell 
transmigration and cytokine/chemokine signalling have been found to be differentially 
overexpressed in PM, DM and IBM[1, 47-50]. Furthermore, cultured muscle cellscan secrete 
proinflammatory cytokines upon stimulation in a positive feedback loop mechanism that 
attracts activated T cells, and Toll-like receptors (TLRs) expressed by muscle tissue from 
patients with inflammatory myopathies enhance cytokine secretion. Therefore, muscle 
fibres in addition to being the target of inflammation contribute tocreating a 
proinflammatory environment that drives disease chronicity[48, 51, 52]. Microarray gene 
expression profiling has detected upregulation of genes for adhesion molecules, cytokines, 
MHC class I molecules, chemokines and immunoglobulins in the muscles of patients with 
inflammatory myopathies[4, 53-56].In particular, the interferons (IFNs)and IFN-inducible 
genes have been strongly implicated in the pathogenesis of myositis. The enhanced type I 
IFN gene signature has been associated with disease activity in both PM and 
  
 
7 
 
DM[57].Additionally,immunostaining for type I IFN has been detected in DM in muscle fibres 
in areas showingperifascular atrophy, as well as in plasmacytoid dendritic cells and in the 
capillary endothelial cells [27, 58].  In contrast,overexpression of the type IIIFN (IFN-ƴ) 
induced genes has been associated with inclusion body myositis, being localised to muscle 
fibres invaded by CD8
+
 T cells[49, 59].  
 
3. IL-17 and Cellular Sources of IL-17 
3.1 Discovery of IL-17 
IL-17 is a pro-inflammatory cytokine demonstrated to contribute to several inflammatory 
and autoimmune diseases[60]. Key sources of IL-17 are the T helper 17 cells (Th17)as well as 
cells from the innate immune system such as mast cells and neutrophils[61, 62]. IL-17 is the 
founding member of the IL-17 cytokine family comprising six members: IL-17 (IL-17A), IL-
17B, IL-17C, IL-17D, IL-17E (also known as IL-25) and IL-17F. IL-17 was first discovered in 
1993 when a molecule termed ‘cytotoxic T-lymphocyte-associated antigen 8’ (CTLA-8) was 
isolated from rodent T cell hybridoma clones. Further work subsequently demonstrated its 
ability to stimulate the production of cytokines from synoviocytes and mesenchymal cells 
[63, 64]. The results of this work and the identification of a receptor led to the naming of a 
novel cytokine IL-17 and its receptor IL-17R[65, 66]. IL-17 and IL-17F share a high degree of 
homology and both bind to the same receptor implying common biological activities.  
Additionally, IL-17 can exist as a homodimer or a heterodimer with IL-17F[67].  
3.2 Th17 cells and other cellular sources of IL-17 
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Upon its discovery, IL-17 was initially described as a T cell product. Subsequent studies 
indicated IL-17 secreting cells were Th1/Th0, not TH2, and hinted that IL-17 may define a 
new subset of Th1 cells[68-72]. Previous to this the pathogenesis of autoimmune diseases 
had been attributed to TH1 cells in line with the Th1/Th2 model devised by Mossman and 
Coffman[73]. This hypothesis was challenged when it was demonstrated that mice deficient 
in IFN-ƴ expression and signalling were still susceptible to mouse models of multiple 
sclerosis and inflammatory arthritis[74]. Eventually, a decade after its discovery,IL-17 
producing Th17 cells were demonstrated to be a distinct lineage from Th1 or Th2 cells and 
to be pathogenic in autoimmunity[75-77]. Th17 cells differentiate from naïve precursor T 
cells (Th0) cells through antigen presentation and co-stimulation and the effects of Th17 
cell-polarizing cytokines (TGF-β, IL-21, IL-6 and IL-23)[67](Figure 1). Subsequent research has 
identified additional non-CD4
+
 cell types that are also key sources ofIL-17 in autoimmune 
and inflammatory diseases, which include CD8+ Tc17 cells, ƴδ T cells, natural killer cells, 
neutrophils and mast cells[61, 62, 78]. Studies suggest that theseadditional IL-17 secreting 
cell types, in particular CD8+ Tc17 cells, may develop under similar inflammatory 
conditionsas Th17 cells and may have common inhibitorycontrol mechanisms[62, 79, 
80].Th17 cells have also been shown to have a similar development pathway but opposing 
effects in the inflammatory response to CD4
+
CD25
+
Foxp3
+
regulatory T cells (Tregs). It is 
recognised that there is a fine balance between Th17 and Tregs in maintaining tissue 
homeostasis and a disruption of this balance can lead to chronic inflammation and 
autoimmunity. Defects in Treg numbersand function have been well characterised in a 
number of inflammatory and autoimmune conditions[81, 82].  
3.3 Biological effects of IL-17  
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The main IL-17-responsive cell types are epithelial cells, endothelial cells, fibroblasts, 
macrophages, anddendritic cells. Furthermore, T cells as well as being producers of IL-17 are 
also responsive to the cytokine. Upon binding to its receptor, IL-17 stimulates downstream 
signalling pathways leading to the activation of several common transcription factors (AP-1, 
NF-κB, PI3K/JAK, C/EBP), inducing the gene transcription of cytokines, chemokines, growth 
factors, MMPs and antimicrobial peptides in target cells[83-85]. Additionally, IL-17 can 
stabilize the mRNA of certain proinflammatory cytokines and chemokines induced by TNF-
α[85]. Furthermore, the IL-17 induction of cytokine and chemokine expression can be 
enhanced by co-stimulation with TNF-α, OncostatinM (OSM)), IL-1β or TLR ligands[72, 84]. 
IL-17 has been shown to play a key role in driving inflammatory cell migration and invasion 
by mediating cytoskeletal rearrangement through the activation of integrin-
linked/RhoGTPase pathways[83]. Recent studies have also demonstrated that IL-17 is able 
to regulate lymphocyte function and was shown to modulate the survival and differentiation 
of antibody producing B cells in mouse models of autoimmune diabetes[86-89].  IL-17 has 
also been shown to promote the polarization and function of TH1 cells in vitro and in 
vivo[90, 91]. 
 
 
4. Potential role for IL-17 in immunopathogenesis of myositis 
4.1 Expression of IL-17 in inflammatory myopathies 
Several studies have investigated the presence of IL-17 in muscle tissue or blood in patients 
with inflammatory myopathies, however these have focused mainly on DM and PM and few 
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on IBM. Immunohistochemistry has detected IL-17 producing cells in Tcell rich areas of DM 
and PM tissue,although the number of IL-17 positive cells was low compared to IFN-γ 
producing cells[92-94].In addition, increased expression of IL-17 mRNA has been 
demonstrated in DM, PM and IBM muscle.The detection of IL-17 was also shown to be 
strongly associated with increased levels of expression of TLR, IFN-ƴ and MyD88in these 
studies [95, 96].Increased protein expression of another Th17 cytokine IL-22 has been 
observed in the tissues of DM and PM patients and correlated with markers of myositis 
activity. Furthermore a number of these IL-22+ T cells co-expressed IL-17 [97]. Increased 
expression of IL-17 has also been demonstrated in whole blood samples from PM and DM 
patients, with a subset of DM patients showing an enhanced IL-17 gene signature rather 
than type I IFN[98]. 
A number of studies have reported increased serum levels of IL-17 in patients with DM or 
PM[99-101] and levels significantly correlated with disease activity[100-102]. Onestudy in 
DM and PM patients found that serum levels of IL-17 were not significantly higher than in 
healthy controls, although this may have been due to the ELISA 
sensitivity[103].Additionally,in an analysis of peripheral blood mononuclear cells (PBMC) 
from IBM patients the percentage of CD3
+
CD4
+
 IL-17
+
 cells was not higher than in healthy 
controls[104]. However, activated PBMC from patients with early PM and DM were shown 
to secrete significantly higher amounts of IL-17 than those with established disease[103]. 
The frequency of Th17 cells[94, 105]in PM and DM PBMCand Th17 cytokines (IL-6, IL-23, IL-
1β and TGF-β) in DM have also been shown to beincreased in comparison to healthy 
controls[105]. IMNM has been characterized by a Th1 immune response however this study 
did not assess IL-17/Th17 expression [14]. 
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4.2 Actions of IL-17 on muscle  
A limited number of studies have explored the direct effects of IL-17 on muscle cells (Figure 
2). The first in 2003 examined the effect of IL-17 alone and in combination with IL-1β on the 
expression of cell-adhesion molecules and cytokine/chemokine production by normal 
human myoblasts andmuscle tissuesamples in vitro[92].IL-17 alone and in combination with 
IL-1β stimulated IL-6 production by myoblasts and cultured muscle samples. While IL-17 
alone had no effect on CCL20 production, IL-17 amplifiedthe effects of IL-1βon IL-6 and 
CCL20 secretion by the muscle explants.In another study the expression of HLA class I, C-
Fos, NF-κB and C-Jun was also found to be increased by IL-17 stimulation[106]. A 
recentstudy demonstrated the ability of IL-17 to inhibit myoblast migration and myogenic 
differentiation in an ERK1,2 dependent manner[107].In a further study IL-17 was shown to 
mediate this effect though the inhibition of urokinase type plasminogen inhibitor (uPA), a 
key molecule in skeletal myogenesis[108]. 
5. Strategies for targeting IL-17 therapeuticallyand relevance to IIM  
5.1 Indirect targeting 
IL-17 has been targeted indirectly in myositis patients using the IL-1 receptor antagonist 
anakinra[109]. The study cohort was heterogeneous and included DM, PM and IBM 
patients.IL-17 expressing CD4+ T cells were reduced in three out of six patients after 6 
months treatment and a shift in T cell differentiation from Th17 to Th1 was observed in 5 
out of 6 patients.  This was confirmed by in vitro studies that showed a reduction inPBMC IL-
17A secretion by PBMCs 92-98%. The TNF inhibitor adalimumab was also tested but showed 
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no inhibitory effect[109].Treatment with rituximab did not result in a decrease of Th17 cells 
in two studies of refractory PM and DM patients[102, 110]. Interestingly, in one study a 
significant increase in Th17 cytokine levels was observed[102]. 
Administration of intravenous immunoglobulin (IVIG) has been shown to be effective in 
patients with DM and PM who are unresponsive to glucocorticoids or immunosuppressive 
drugs[111-114].Expression of IL-17 and IFN-ƴ was quantified in muscle biopsies from a 
cohort of 13 myositis patients (11PM and 2DM) pre- and post-IVIG treatment,seven of 
whom were defined asbeing responders. IL-17 and IFN-ƴ positive cells were detected in 
11/13 patients. The numbers ofIFN-ƴ positive cells and the ratioof IFN- ƴ/IL-17-producing 
cells were significantly higher in non-responders than responders,but there was no 
differential expression of IL-17 producing cells in the two groups. These observations 
suggest that the Th1/Th17 cell balance is important in determining the response to IVIG 
therapy in myositis[94]. 
5.2 Induction of regulatory T cells  
A number of autoimmune or inflammatory diseases are characterized by a decrease in Treg 
cell numbers and/or function. Foxp3+ T regulatory cells have been detected in patients with 
DM, PM and IBM and their numbers have been found to inversely correlate with the 
severity of disease activity[115]. The number of circulating Tregs in patients with IBM and 
DM has been documented to be lower than in healthy controls[116, 117]. Furthermore, the 
serum levels of the Treg associated cytokines TGF-β and IL-10 are significantly reduced in 
DM patients[116]. The induction/and or expansion of Tregs is currently being examined as a 
therapeutic strategy in the treatment of inflammatory diseases, in particular as an inhibitor 
of Th17-mediated autoimmunity[118, 119]. The balance between Th17 and Treg cells in 
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myositis patients has not been well characterised. One study in IBM patients described an 
enhanced Th1 profile with decreased Treg numbers compared to controls, however no 
increase in Th17 cells was found[117].   
5.3 Targeting of Th17 related molecules 
IL-6 is a key factor in the differentiation of CD8
+
 Tc17 and Th17 cells[67] and studies suggest 
the cytokine plays an important role in myositis, in particular in PM[120]. Overexpression of 
IL-6 has been detected in the serum and muscle tissue of patients with IBM, PM and 
DM[121-123]. Furthermore, in mouse models of myositis inhibiting IL-6 by gene knockout or 
with an anti-IL-6 receptor antibody ameliorated myositis severity. Toculizumab, a 
humanized anti-IL-6 receptor antibody, has been shown to be successful in the treatment of 
two patients with resistant PM[124].   
The differentiation of IL-17 secreting T cells such as Th17 and CD8 Tc17 cells requires the 
expression of the ‘retinoic acid receptor-related orphan nuclear receptor’ RORƴt[124, 125]. 
A number of RORƴt small-molecule inhibitors have been identified and have been shown to 
inhibit the differentiation and function of Th17 and CD8Tc17 cells[80, 126]. This approach is 
thought to be particularly advantageous as targeting RORƴt inhibits not only Th17 
differentiation and IL-17 secretion but also the production of other proinflammatory 
cytokines secreted by Th17 cells. Furthermore, RORƴt agonists could potentially be 
delivered orally in comparison to the other injectable biologic therapies. A number of these 
molecules are currently in clinical development [127, 128].  
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5.4 Direct Targeting of IL-17 
A number of monoclonal antibodies directly targeting IL-17A and its receptor are currently 
undergoing clinical trials for the treatment of a variety of inflammatory and autoimmune 
diseases including psoriasis, rheumatoid and psoriatic arthritis, ankylosing spondylitis, 
multiple sclerosis and asthma[67, 128] but as yet have not been trialled in inflammatory 
myopathies. Clinical trials assessing IL-17 inhibitors for the treatment of psoriasis are the 
most advanced, with the IL-17A inhibitor secukinumab having completed phase III trials late 
last year and are expected to receive approval. Two other inhibitors targeting IL-17A 
(Ixekizumab) and its receptor IL-17R (Brodalumab) are currently in phase IIItrials in psoriasis 
patients [128]. Results from trials to date suggest that the success of IL-17 inhibition is 
dependent on the specific tissue, cellular and immunological context. For example anti-IL-
17A antibodies are showing success in psoriasis and multiple sclerosis but not in Crohn’s 
disease [60]. 
6.  Conclusions 
IL-17A has been firmly established as a key mediator in the pathogenesis of a number of 
chronic inflammatory and autoimmune diseases such as psoriasis and rheumatoid arthritis. 
The investigations into the efficacy of pharmacological inhibitors targeting the IL-17 
pathway are at an advanced stage and the approval of at least one anti-IL-17A drug for the 
treatment of these conditions is expected imminently. The detection of IL-17A in muscle 
tissue of myositis patients and in vitro studies suggest that IL-17Aalso playsan important role 
in the pathogenesis of the inflammatory myopathies and may be a potential therapeutic 
target in cases resistant to treatment. To date, these studies have been limited and have 
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mainly focused on PM and DM rather than IBM. Further studies examining the expression 
profile of IL-17A in the different inflammatory myopathies, as well as the cellular sources of 
IL-17A are necessary to fully elucidate the contribution of this proinflammatory cytokine to 
disease pathogenesis.  
Search Strategy and selection criteria  
Pubmed was searched from 1990 to 2014 using the terms inflammatory myopathies, 
dermatomyositis, polymyositis, inclusion body myositis, muscle, IL-17, Th17, cytotoxic T cells 
and cellular sources of IL-17. We also identified further articles through searches of 
reference lists from these articles. We reviewed only articles published in the English 
language.  
 
 
Figure Captions  
Figure 1. Differentiation pathways, cytokine profiles and functions of Th1, Th2, Th17 and 
Treg cell subsets 
Figure 2. Putative mechanisms of action of IL-17 on myoblasts and downstream effects.IL-
17RA and IL-17RC represent the A and C chains of the IL-17 receptor; TLR: Toll-like 
receptors; GPCR: G-protein coupled receptor; HLA-I: Human Leukocyte Antigen Class 1; NF-
κB; nuclear factor kappa-light-chain-enhancer of activated B cells. 
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Highlights  
• CD4+ Th1 cells or CD8+ cytotoxic T cells have been associated withmyositis  
 
• IL-17 and Th17 cells have been implicated in autoimmunityresulting in IL-17 targeted 
therapies 
 
• We reviewthe IL-17/Th17 axis in myositis and the therapeutic potential 
 
• Detection of IL-17 in myositis and in vitro studies suggestsa key role in myositis 
 
